3.0
7 Jan 2015
Anonymous employee
Former employee
Recommend
CEO approval
Business outlook
Pros
Diversity in Oncology portfolio, very strong in oncology.
Cons
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.